Abstract:BACKGROUND: Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca 2+ /calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders. METHODS: To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ. We generated mice harboring a phospho-resistant CaMKIIδ mutation in the germline and subjected these mice to severe transverse aortic constriction, a model for heart failure. Cardiac function, transcriptional changes, apoptosis, and fibrosis were assessed by echocardiography, RNA sequencing, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and standard histology, respectively. Specificity toward CaMKIIδ gene editing was assessed using deep amplicon sequencing. Cellular Ca 2+ homeostasis was analyzed using epifluorescence microscopy in Fura-2–loaded cardiomyocytes. RESULTS: Within 2 weeks after severe transverse aortic constriction surgery, 65% of all wild-type mice died, and the surviving mice showed a dramatically impaired cardiac function. In contrast to wild-type mice, CaMKIIδ phospho-resistant gene-edited mice showed a mortality rate of only 11% and exhibited a substantially improved cardiac function after severe transverse aortic constriction. Moreover, CaMKIIδ phospho-resistant mice were protected from heart failure–related aberrant changes in cardiac gene expression, myocardial apoptosis, and subsequent fibrosis, which were observed in wild-type mice after severe transverse aortic constriction. On the basis of identical mouse and human genome sequences encoding the autophosphorylation site of CaMKIIδ , we deployed the same editing strategy to modify this pathogenic site in human induced pluripotent stem cells. It is notable that we detected a >2000-fold increased specificity for editing of CaMKIIδ compared with other CaMKII isoforms, which is an important safety feature. Although wild-type cardiomyocytes showed impaired Ca 2+ transients and an increased frequency of arrhythmias after chronic β-adrenergic stress, CaMKIIδ -edited cardiomyocytes were protected from these adverse responses. CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.

Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice

Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy

Allele-Specific Suppression of Variant MHC with High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy.

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia

Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy

Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice

Long-term therapeutic efficacy and safety profiles of hpCas13d RNA editing in treating early-onset hypertrophic cardiomyopathy

Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice

Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome

Abstract 11841: Gene Therapy Improves Pathological Cardiac Remodeling in Human Hypertrophic Cardiomyopathy Gene Variant Knock-In Mice

Correction of Diverse Muscular Dystrophy Mutations in Human Engineered Heart Muscle by Single-Site Genome Editing

CRISPR-Cas9 Base Editing of Pathogenic CaMKIIδ Improves Cardiac Function in a Humanized Mouse Model.

In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice

Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM

CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy